Intracellular Protein Binding of Zr-89 Oxine Cell Labeling for PET Cell Tracking Studies

<b>Background/Objectives</b>: <sup>89</sup>Zr-oxine is an ex vivo cell labeling agent that enables cells to be tracked in vivo by positron emission tomography (PET) over a period of up to two weeks. To better understand where <sup>89</sup>Zr-oxine binds within cellular components, factors affecting labeling and intracellular distribution of <sup>89</sup>Zr were examined. <b>Methods</b>: Mouse primary T cells, natural killer cells, dendritic cells, and monocytes, and cell lines EL4 (mouse lymphoma), DC2.4 (mouse dendritic cell), Kit225K6 (human T cell leukemia) and MC38 (mouse colon adenocarcinoma) were labeled with <sup>89</sup>Zr-oxine or <sup>111</sup>In-oxine and protein binding within the cellular compartments, the labeling thresholds, and radioactivity retention were subsequently determined. <b>Results</b>: Cell incorporation of <sup>89</sup>Zr-oxine (27.8-71.8 kBq/10<sup>6</sup> cells) positively correlated with cellular size and protein mass. Most (>97%) <sup>89</sup>Zr was protein-bound and primarily localized in the cytoplasm, membrane, and nuclear fractions (>81%) with distribution patterns varying by cell type. By contrast, <sup>111</sup>In-oxine showed lower protein-binding activity of approximately 59-65%, with 62-65% of <sup>111</sup>In localized in the cytoplasm. Autoradiography of electrophoresed subcellular fractionated cell samples indicated stable binding by <sup>89</sup>Zr-oxine to proteins in all subcellular fractions but unstable protein binding by <sup>111</sup>In. Saturation studies showed that <sup>89</sup>Zr-oxine labeling was saturable, and further labeling reduced cellular retention. Biodistribution of dendritic cells labeled with either <sup>89</sup>Zr-oxine or <sup>111</sup>In-oxine indicated greater retention of <sup>89</sup>Zr in the labeled cells in vivo than <sup>111</sup>In. <b>Conclusions</b>: <sup>89</sup>Zr-oxine stably binds many intracellular proteins and shows much higher and more stable protein binding than <sup>111</sup>In-oxine. Intracellular protein binding of <sup>89</sup>Zr accounts for the ability of <sup>89</sup>Zr-oxine labeling to successfully track cells in vivo long-term on PET.

Authors

Institutions

Publication Details

Journal
Pharmaceutics
Published
2025-04-15
DOI
https://doi.org/10.3390/pharmaceutics17040518
Citations
1
Primary Topic
Radiopharmaceutical Chemistry and Applications
Type
article
Field-Weighted Citation Impact
1.36

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Intracellular Protein Binding of Zr-89 Oxine Cell Labeling for PET Cell Tracking Studies

Kingsley O. Asiedu, Noriko Sato, Emmanuel Nyong, Yutaka Kurebayashi et al.
1 citations
Pharmaceutics
Radiopharmaceutical Chemistry and Applications
1.36
article

Intracellular Protein Binding of Zr-89 Oxine Cell Labeling for PET Cell Tracking Studies

Kingsley O. Asiedu, Noriko Sato, Emmanuel Nyong, Yutaka Kurebayashi, Peter L. Choyke
article en
1 citations

Abstract

<b>Background/Objectives</b>: <sup>89</sup>Zr-oxine is an ex vivo cell labeling agent that enables cells to be tracked in vivo by positron emission tomography (PET) over a period of up to two weeks. To better understand where <sup>89</sup>Zr-oxine binds within cellular components, factors affecting labeling and intracellular distribution of <sup>89</sup>Zr were examined. <b>Methods</b>: Mouse primary T cells, natural killer cells, dendritic cells, and monocytes, and cell lines EL4 (mouse lymphoma), DC2.4 (mouse dendritic cell), Kit225K6 (human T cell leukemia) and MC38 (mouse colon adenocarcinoma) were labeled with <sup>89</sup>Zr-oxine or <sup>111</sup>In-oxine and protein binding within the cellular compartments, the labeling thresholds, and radioactivity retention were subsequently determined. <b>Results</b>: Cell incorporation of <sup>89</sup>Zr-oxine (27.8-71.8 kBq/10<sup>6</sup> cells) positively correlated with cellular size and protein mass. Most (>97%) <sup>89</sup>Zr was protein-bound and primarily localized in the cytoplasm, membrane, and nuclear fractions (>81%) with distribution patterns varying by cell type. By contrast, <sup>111</sup>In-oxine showed lower protein-binding activity of approximately 59-65%, with 62-65% of <sup>111</sup>In localized in the cytoplasm. Autoradiography of electrophoresed subcellular fractionated cell samples indicated stable binding by <sup>89</sup>Zr-oxine to proteins in all subcellular fractions but unstable protein binding by <sup>111</sup>In. Saturation studies showed that <sup>89</sup>Zr-oxine labeling was saturable, and further labeling reduced cellular retention. Biodistribution of dendritic cells labeled with either <sup>89</sup>Zr-oxine or <sup>111</sup>In-oxine indicated greater retention of <sup>89</sup>Zr in the labeled cells in vivo than <sup>111</sup>In. <b>Conclusions</b>: <sup>89</sup>Zr-oxine stably binds many intracellular proteins and shows much higher and more stable protein binding than <sup>111</sup>In-oxine. Intracellular protein binding of <sup>89</sup>Zr accounts for the ability of <sup>89</sup>Zr-oxine labeling to successfully track cells in vivo long-term on PET.

PharmaceuticsVol. 17(4)
National Institutes of Health (US), Keio University (JP), Duke Medical Center (US), National Cancer Institute (US), Center for Cancer Research (US), Duke University Hospital (US), The University of Texas Medical Branch at Galveston (US)
National Institutes of Health, National Cancer Institute, NIH Clinical Center
Openalex Percentile: Top 21%
Radiopharmaceutical Chemistry and Applications
1.36
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.